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Previous work linked nitric oxide (NO) signaling to histone deacetelyases (HDACs) in the control of tissue
homeostasis and suggested that deregulation of this signaling contributes to human diseases. In the previ-
ous issue of Chemistry & Biology, Kong and colleagues showed that coordinated NO signaling and histone
acetylation are required for proper cranial neural crest development and craniofacial morphogenesis and
suggested that alterations of NO/acetylation network can contribute to the pathogenesis of craniofacial
malformations.In order to get a full picture of the interplay
between genetic and epigenetic factors in
the molecular pathogenesis of congenital
disorders, we need to improve our under-
standing of how developmental cues are
converted into epigenetic modifications
that control the expression of specific
subsets of genes during lineage determi-
nation. Indeed, genetic mutations that
compromise the integrity of histone-
modifying complexes involved in epige-
netic regulation have been associated
with malformations and might account
for differences in disease penetrance
and severity caused by changes in envi-
ronmental exposure. Craniofacial forma-
tion provides a notable example of a
developmental process that is tightly
regulated at the epigenetic level, as
gene mutations altering the activity of
enzymes that regulate histone acetyla-
tion, methylation, and sumoylation result
in orofacial malformations (Alkuraya
et al., 2006; Fischer et al., 2006; Qi et al.,
2010; Kraft et al., 2011; DeLaurier et al.,
2012).
In the previous issue of Chemistry &
Biology, Kong et al. (2014) used a
chemical genetics screen in zebrafish
embryos to discover molecular deter-
minants of craniofacial development
during embryogenesis. Using both gene
(crestin) expression-based and pheno-
typic screening, they identified a nitric
oxidase synthase inhibitor (TRIM) that
impairs cranial neural crest (CNC) devel-
opment by inhibiting migration of CNC
cells and their differentiation into the
chondrocyte lineage. This phenotypecan be rescued by implementing histone
acetylation through either overexpression
of the acetyltransferase (HAT) kat6a or
pharmacological blockade of histone
deacetelyases (HDACs) by Trichostatin A
(TSA), indicating a functional relationship
between NO (nitric oxide) signaling and
histone acetylation for proper CNC
development and craniofacial morpho-
genesis (Figure 1). Cell lineage tracing
and gene expression analysis support
the conclusion that NO is an upstream
signal that controls the balance between
HATs and HDAC during CNC cell lineage
determination; however, the authors
could not conclusively work out the func-
tional and biochemical details underlying
NO-mediated control of histone acetyla-
tion. The finding that nuclei of TRIM-
treated embryos show decreased (by
half) levels of acetylated histone H4 are
clearly in support of a physiological in-
hibitory action of NO on histone acetyla-
tion. Still, it remains unclear whether NO
signaling directly targets histone-modi-
fying complexes to regulate gene expres-
sion in CNC cells.
Previous work has revealed that
S-nitrosylation of HDACs is a posttran-
scriptional modification that couples NO
production to chromatin remodeling and
regulation of gene expression in adult
tissues (Colussi et al., 2008; Nott et al.,
2008). NO is a second messenger
signaling molecule generated by the NO
synthase (NOS) family of enzymes that
regulatesmany developmental processes
(Moncada and Higgs, 1993) via cysteine
nitrosylation (S-nitrosylation) of proteinsChemistry & Biology 21, May 22, 2014and transcription factors (Hess and
Stamler, 2012). S-nitrosylation of HDAC2
provided seminal evidence in support of
a direct NO-regulated chromatin remod-
eling in neuronal development (Nott
et al., 2008) and skeletal muscle homeo-
stasis (Colussi et al., 2008). Interestingly,
deregulated NO signaling to HDAC2 has
been reported in the muscles of the
Mdxmouse model of Duchenne muscular
dystrophy (DMD) because of the absence
of the nNOS-interacting dystrophin do-
main, which ultimately leads to constitu-
tive activation of HDAC2 (Colussi et al.,
2008). The beneficial effect of HDAC
inhibitors and NO donors in Mdx mice
(Minetti et al., 2006, Brunelli et al., 2007)
suggests that alteration of NO-HDAC
signaling contributes to DMD patho-
genesis and indicates the potential thera-
peutic relevance of the pharmacological
control of NO-mediated nitrosylation of
HDAC.
Kong et al. (2014) show that TRIM-
induced phenotype is more effectively
rescued by complementary NO produc-
tion than by gain-of-function approaches
that implement histone acetylation (i.e.,
HAT overexpression or HDAC inhibition).
This evidence, while positioning NO
upstream of HAT/HDAC, also indicates
alternative ways by which NO can regu-
late gene expression in CNC cells—e.g.,
by direct S-nitrosylation of histone
or transcription factors. However, the au-
thors failed to detect general alterations
in S-nitrosylation of total proteins upon
TRIM treatment by using biotin






Figure 1. Schematic Representation of NO-
Mediated Control of Gene Expression
Nitric oxide (NO) signaling can influence gene
expression of specific cell types, such as cranial
neural crest (CNC) cells during development, by
S-nitrosylation of enzymes that promote (histone
acetyltransferases [HAT]) or inhibit (histone deace-
tylases [HDAC]) histone acetylation or by direct tar-
geting histones or transcription factors (TF).
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are required to capture S-nitrosylation
of potential epigenetic effector(s) of NO-
mediated regulation of gene expression
and lineage determination of CNC cells.566 Chemistry & Biology 21, May 22, 2014 ªDevelopmental processes are often
resumed during adult life, and their alter-
ations might contribute to the pathogen-
esis and progression of human diseases.
As aberrant protein S-nitrosylation is
implicated in the pathogenesis of neuro-
degenerative diseases (Nakamura et al.,
2013), further elucidation of the molecular
and biochemical relationship between
NO, acetylation, and gene expression in
specific cell types of interest, such as
tissue progenitors during embryo devel-
opment and postnatal tissue homeostasis
or repair, might uncover pathological
events in common between develop-
mental and adult disorders.
Overall, the study by Kong et al. (2014)
emphasizes the power of the chemical
genetic screening in the zebrafish embryo
as a tool to identify novel pathways gov-
erning specific developmental stages
and potential targets of pharmacological
approaches aimed at preventing genetic
malformations and countering the pro-
gression of certain adult diseases.REFERENCES
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